JP2022517109A5 - - Google Patents
Info
- Publication number
- JP2022517109A5 JP2022517109A5 JP2021540533A JP2021540533A JP2022517109A5 JP 2022517109 A5 JP2022517109 A5 JP 2022517109A5 JP 2021540533 A JP2021540533 A JP 2021540533A JP 2021540533 A JP2021540533 A JP 2021540533A JP 2022517109 A5 JP2022517109 A5 JP 2022517109A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- cancer
- cancers
- alkyl
- pharmaceutically acceptable
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962791979P | 2019-01-14 | 2019-01-14 | |
| US62/791,979 | 2019-01-14 | ||
| PCT/US2020/013264 WO2020150115A1 (en) | 2019-01-14 | 2020-01-13 | Nlrp3 modulators |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022517109A JP2022517109A (ja) | 2022-03-04 |
| JPWO2020150115A5 JPWO2020150115A5 (https=) | 2022-09-05 |
| JP2022517109A5 true JP2022517109A5 (https=) | 2022-09-05 |
| JP7335341B2 JP7335341B2 (ja) | 2023-08-29 |
Family
ID=69469246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540533A Active JP7335341B2 (ja) | 2019-01-14 | 2020-01-13 | Ｎｌｒｐ３モジュレーター |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12391675B2 (https=) |
| EP (1) | EP3911641A1 (https=) |
| JP (1) | JP7335341B2 (https=) |
| KR (1) | KR102865929B1 (https=) |
| CN (1) | CN113286786A (https=) |
| WO (1) | WO2020150115A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020150116A1 (en) | 2019-01-14 | 2020-07-23 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| WO2023032987A1 (ja) * | 2021-08-31 | 2023-03-09 | 日本たばこ産業株式会社 | ６－アミノピラゾロピリミジン化合物及びその医薬用途 |
| CN115282280A (zh) * | 2022-08-12 | 2022-11-04 | 中国科学技术大学 | TGF-β1信号抑制剂的新用途 |
| WO2024177127A1 (ja) * | 2023-02-24 | 2024-08-29 | 日本たばこ産業株式会社 | 置換ピラゾロピリミジン化合物及びその医薬用途 |
| EP4671246A1 (en) * | 2023-02-24 | 2025-12-31 | Japan Tobacco Inc. | COMPOSITE OF 6-ALCOXYPYRAZOLOPYRIMIDINE AND ITS PHARMACEUTICAL USE |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1141028T3 (da) | 1998-12-23 | 2010-05-25 | Pfizer | Humane monoklonale antistoffer til CTLA-4 |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| US20140243302A1 (en) | 2011-06-27 | 2014-08-28 | Merck Sharp & Dohme Corporation | Bridged bicyclic compounds for the treatment of bacterial infections |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| HK1204557A1 (en) | 2012-05-31 | 2015-11-27 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-l1 |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| RS59500B1 (sr) | 2013-05-18 | 2019-12-31 | Aduro Biotech Inc | Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“ |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| MY184154A (en) | 2013-12-12 | 2021-03-23 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| MA44594B1 (fr) | 2015-05-29 | 2020-09-30 | Memorial Sloan Kettering Cancer Center | Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| CN111491361B (zh) | 2016-02-02 | 2023-10-24 | 华为技术有限公司 | 确定发射功率的方法、用户设备和基站 |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| CA3021349A1 (en) * | 2016-04-19 | 2017-10-26 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| TWI674261B (zh) * | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
| MY201080A (en) * | 2017-07-14 | 2024-02-03 | Innate Tumor Immunity Inc | Nlrp3 modulators |
| WO2020150116A1 (en) * | 2019-01-14 | 2020-07-23 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| ES2930151T3 (es) * | 2019-01-14 | 2022-12-07 | Innate Tumor Immunity Inc | Moduladores heterocíclicos de NLRP3, para su uso en el tratamiento del cáncer |
-
2020
- 2020-01-13 EP EP20703911.6A patent/EP3911641A1/en active Pending
- 2020-01-13 WO PCT/US2020/013264 patent/WO2020150115A1/en not_active Ceased
- 2020-01-13 JP JP2021540533A patent/JP7335341B2/ja active Active
- 2020-01-13 KR KR1020217025495A patent/KR102865929B1/ko active Active
- 2020-01-13 CN CN202080008819.6A patent/CN113286786A/zh active Pending
- 2020-01-13 US US17/422,512 patent/US12391675B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022517109A5 (https=) | ||
| JP2021534168A5 (https=) | ||
| JP2021522249A5 (https=) | ||
| JP2021534158A5 (https=) | ||
| JP7274450B2 (ja) | 癌を処置するための医薬組合せ | |
| ES2290199T3 (es) | Mezcla que incluye un agente que reduce la actividad de fcve y un agente que reduce la actividad de fce. | |
| JP2025024006A5 (https=) | ||
| KR20210075992A (ko) | Sting 작동 화합물 | |
| WO2019136298A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| JP2016528162A (ja) | がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用 | |
| JP2022517110A5 (https=) | ||
| ES2653990T3 (es) | Benzodiazepinas para tratamiento del cáncer de pulmón de células pequeñas | |
| RU2007110480A (ru) | Терапевтические комбинации, содержащие ингибитор поли(адф-рибоза)полимеразы | |
| JP2016523974A5 (https=) | ||
| JP6425653B2 (ja) | 抗腫瘍剤及び抗腫瘍効果増強剤 | |
| RU2020113749A (ru) | Аналоги таиланстатина | |
| MX2013008749A (es) | Agente terapeutico o profilactico para caquexia. | |
| CA3080644A1 (en) | Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer | |
| JPWO2020037091A5 (https=) | ||
| JPWO2019209896A5 (https=) | ||
| JPWO2021155264A5 (https=) | ||
| WO2021007402A1 (en) | Peptide conjugates of microtubule-targeting agents as therapeutics | |
| RU2013143520A (ru) | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний | |
| JPWO2020037092A5 (https=) | ||
| RU2334517C2 (ru) | Средство, потенцирующее противоопухолевый эффект, и противоопухолевое средство |